There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioNano Genomics (BNGO – Research Report), Legend Biotech (LEGN – Research Report) and Delcath Systems (DCTH – Research Report) with bullish sentiments.
BioNano Genomics (BNGO)
In a report released yesterday, Mark Massaro from BTIG reiterated a Buy rating on BioNano Genomics, with a price target of $6.00. The company’s shares closed last Thursday at $1.14, close to its 52-week low of $1.10.
According to TipRanks.com, Massaro is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on BioNano Genomics is a Strong Buy with an average price target of $9.00, representing a 662.7% upside. In a report issued on January 19, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $14.00 price target.
See today’s best-performing stocks on TipRanks >>
Legend Biotech (LEGN)
In a report released yesterday, Justin Zelin from BTIG reiterated a Buy rating on Legend Biotech, with a price target of $91.00. The company’s shares closed last Thursday at $56.22.
According to TipRanks.com, Zelin is a 5-star analyst with an average return of
Currently, the analyst consensus on Legend Biotech is a Strong Buy with an average price target of $88.19, implying a 59.7% upside from current levels. In a report issued on January 18, Jefferies also maintained a Buy rating on the stock with a $93.00 price target.
Delcath Systems (DCTH)
BTIG analyst Marie Thibault reiterated a Buy rating on Delcath Systems yesterday and set a price target of $16.00. The company’s shares closed last Thursday at $4.72.
According to TipRanks.com, Thibault is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Delcath Systems with a $17.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BNGO:
- Bionano to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science & Diagnostic Tools Conference
- Bionano Genomics announces conclusion of 2024 Symposium
- Bionano Genomics announces publication of study on OGM
- Bionano Announces Publication of Interim Readout from Second Phase of Clinical Trial Analyzing Optical Genome Mapping as Standard of Care (SOC) for Prenatal Testing
- Bionano Genomics announces publication of second interim report of trial on OGM
